Success Story: Targeting Cancer Resistance and Molecular Therapy Pathways Through Rapid EB1A Approval for a Cancer Researcher
Client’s Testimonial:
"I highly recommend Chen Immigration for EB-1A petitions. With their expert guidance, my I-140 was approved under premium processing in just 12 days. The team is highly professional, detail-oriented, and responsive throughout the process. If you are looking for reliable and efficient support for your EB-1A case, Chen is an excellent choice.”
On March 16th, 2026, we received another EB-1A (Alien of Extraordinary Ability) approval for a Research Scientist in the Field of Cancer Research (Approval Notice).
General Field: Cancer Research
Position at the Time of Case Filing: Research Scientist
Country of Origin: China
State of Residence at the Time of Filing: Virginia
Approval Notice Date: March 16th, 2026
Processing Time: 17 days (Premium Processing Requested)
Case Summary:
Some EB1A cases are strongest not because they rest on a single headline achievement, but because the record shows repeated, field-wide reliance on a researcher’s work. That was the story here. In just 17 days, through Direct Premium Processing at filing, the client secured approval of the I-140 EB1A petition. With a Ph.D. and an M.S. in cell biology, the client has built a research career in cancer biology, with a particular focus on tumor resistance, non-coding RNA, and molecular target therapy. The petition emphasized that the client is especially recognized for work on targeting CRL4CUL4A/DDB1 to address drug resistance in ovarian cancer, while also advancing research relevant to hematologic malignancies and prostate cancer. The filing further showed that the client is continuing this work in the United States in a research scientist role focused on cancer-related molecular mechanisms.
For EB1A classification, metrics matter only when they help show sustained acclaim and influence. We therefore framed the client’s 15 peer-reviewed journal articles, including 4 first-authored and 5 co-first-authored papers, as evidence of a sustained pattern of original scholarship rather than simple output. The same approach guided the discussion of peer review. The client had completed at least 70 reviews, which is meaningful because journals entrust that role to researchers whose judgment is already respected in the field.
The petition also showed that the client’s research attracted major support from organizations such as the National Cancer Institute, the National Institutes of Health, Blood Cancer United, the Miles for Moffitt Foundation, the Pentecost Family Foundation, the National Clinical Research Center for Geriatrics, the National Natural Science Foundation of China, and the National Key Research and Development Program of China. In adjudicative terms, this kind of funding helps confirm that the research questions being pursued are important, competitive, and independently validated.
Just as important, the case demonstrated that the client’s work was being used by other researchers across the field. The petition documented broad citation influence and explained how the client’s findings helped other scientists study chemoresistance, metastasis, apoptotic signaling, and targeted therapy. That is the type of evidence that helps establish original contributions of major significance under EB1A.
The filing also included 6 recommendation letters, which reinforced the significance of the client’s contributions and placed the objective evidence into context.
“To conclude, it is clear that [Client] stands at the top of her field, given her achievements in areas such as improving patient care and combating cancer cell resistance. Ensuring the continuation of [Client’s] work is thus deeply important to both cancer research and to the nation.”
We congratulate our client on this I-140 EB1A approval and look forward to the continued impact of the client’s cancer research.